Abstract
SEVERAL workers1 have reported the lysis of fibrin clots by staphylococci, and this has been assumed to be due to a fibrinolysin produced by the bacteria.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Maddison, R. R., Proc. Soc. Exp. Biol. Med., 33, 209 (1935).
Christensen, L. R., J. Gen. Phys., 28, 363 (1945).
Loomis, E. C., George, C., and Ryder, A., Arch. Biochem., 12, 1 (1947).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LACK, C. Staphylokinase : an Activator of Plasma Protease. Nature 161, 559–560 (1948). https://doi.org/10.1038/161559b0
Issue Date:
DOI: https://doi.org/10.1038/161559b0
This article is cited by
-
Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion
Molecular Biology Reports (2020)
-
Expression of recombinant staphylokinase in the methylotrophic yeast Hansenula polymorpha
BMC Biotechnology (2012)
-
Streptokinase—the drug of choice for thrombolytic therapy
Journal of Thrombosis and Thrombolysis (2007)
-
Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent
Nature Medicine (1998)
-
Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential
Nature Structural & Molecular Biology (1997)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.